PharmaCielo Cannabis Co. Reports 270% YoY Increase In Q3 Revenue, Confident About Profitability In 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 02 2024
0mins
Source: Benzinga
Financial Performance: PharmaCielo Ltd reported a significant increase in revenue for Q3 2024, totaling CA$1.3 million, up from CA$352,000 the previous year, with total revenues for nine months reaching CA$2.4 million compared to CA$1.3 million in 2023.
Future Outlook: The company aims for profitability in 2025 by leveraging its cultivation capabilities in Colombia and expanding its product portfolio with higher-margin offerings, including psychoactive flower and full-spectrum extracts.
Analyst Views on PCLO
Wall Street analysts forecast PCLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PCLO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
0 Buy
0 Hold
0 Sell
Current: 24.925
Low
Averages
High
Current: 24.925
Low
Averages
High
No data
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
